Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
Rank in Stocks #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Share Price
$1.51
Last synced: 2024-08-26
Market Cap
$1.12M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Agile Therapeutics, Inc. (AGRX)

Category

Revenue for Agile Therapeutics, Inc. (AGRX)
Revenue in Jun 2024 TTM: $21.57M
According to Agile Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is $21.57M. In 2022 the company made a revenue of $10.88M an increase over the revenue in the year 2021 that was $4.10M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Agile Therapeutics, Inc. from 2012 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $21.57M 10.08%
2023 $19.59M 80.02%
2022 $10.88M 165.40%
2021 $4.10M 447.53%
2020 $749.00K 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Revenue for similar companies or competitors